CH626886A5 - - Google Patents

Download PDF

Info

Publication number
CH626886A5
CH626886A5 CH42377A CH42377A CH626886A5 CH 626886 A5 CH626886 A5 CH 626886A5 CH 42377 A CH42377 A CH 42377A CH 42377 A CH42377 A CH 42377A CH 626886 A5 CH626886 A5 CH 626886A5
Authority
CH
Switzerland
Prior art keywords
acid
compounds
formula
symbols
acid addition
Prior art date
Application number
CH42377A
Other languages
German (de)
English (en)
Inventor
Klaus Peter Bogeso
Anders Stausboll Toft
Original Assignee
Kefalas As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9722860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CH626886(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kefalas As filed Critical Kefalas As
Publication of CH626886A5 publication Critical patent/CH626886A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CH42377A 1976-01-14 1977-01-13 CH626886A5 (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1486/76A GB1526331A (en) 1976-01-14 1976-01-14 Phthalanes

Publications (1)

Publication Number Publication Date
CH626886A5 true CH626886A5 (ko) 1981-12-15

Family

ID=9722860

Family Applications (3)

Application Number Title Priority Date Filing Date
CH42377A CH626886A5 (ko) 1976-01-14 1977-01-13
CH357481A CH632258A5 (de) 1976-01-14 1981-06-01 Verfahren zur herstellung von neuen phthalanen.
CH357581A CH632259A5 (de) 1976-01-14 1981-06-01 Verfahren zur herstellung von neuen phthalanen.

Family Applications After (2)

Application Number Title Priority Date Filing Date
CH357481A CH632258A5 (de) 1976-01-14 1981-06-01 Verfahren zur herstellung von neuen phthalanen.
CH357581A CH632259A5 (de) 1976-01-14 1981-06-01 Verfahren zur herstellung von neuen phthalanen.

Country Status (19)

Country Link
US (1) US4136193A (ko)
JP (1) JPS52105162A (ko)
AT (1) AT359488B (ko)
AU (1) AU509445B2 (ko)
BE (1) BE850401A (ko)
CA (1) CA1094087A (ko)
CH (3) CH626886A5 (ko)
DE (1) DE2657013C2 (ko)
DK (1) DK143275C (ko)
ES (1) ES454980A1 (ko)
FI (1) FI63754C (ko)
FR (1) FR2338271A1 (ko)
GB (1) GB1526331A (ko)
IE (1) IE44055B1 (ko)
NL (2) NL192451C (ko)
NO (2) NO147243C (ko)
NZ (1) NZ183001A (ko)
SE (1) SE429551B (ko)
ZA (1) ZA7757B (ko)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602035A (en) * 1983-12-07 1986-07-22 Hoechst-Roussel Pharmaceuticals Inc. Antidepressant (3-aryl-2,3-dihydrobenzofuran-3-yl)alkylamines
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
DE69607904T2 (de) * 1995-08-16 2000-10-05 Eli Lilly And Co., Indianapolis Potenzierung von Serotonin-Wirkstoffresponz
EA001728B1 (ru) * 1997-07-08 2001-08-27 Х.Лундбекк А/С Способ получения циталопрама
UA62985C2 (en) * 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
EP1042310B1 (en) * 1997-11-11 2002-07-31 H. Lundbeck A/S Method for the preparation of citalopram
HU228576B1 (en) 1998-10-20 2013-04-29 Lundbeck & Co As H Method for the preparation of citalopram
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
KR20010081071A (ko) 1998-12-08 2001-08-25 피터슨 존 메이달 벤조푸란 유도체, 그것들의 제조 및 사용
PT1140886E (pt) 1998-12-23 2003-08-29 Lundbeck & Co As H Metodo para a preparacao de 5- cianoftalida
AR022329A1 (es) 1999-01-29 2002-09-04 Lundbeck & Co As H Metodo para la preparacion de 5-cianoftalida
DE69907037T3 (de) * 1999-04-14 2010-02-18 H. Lundbeck A/S Verfahren zur herstellung von citalopram
ITMI991581A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991579A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991486A1 (it) * 1999-07-06 2001-01-06 Vis Farmaceutici S P A Processo per la sintesi di citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
ES2282365T3 (es) 1999-10-25 2007-10-16 H. Lundbeck A/S Metodo para la preparacion de citalopram.
ES2229774T3 (es) 1999-10-25 2005-04-16 H. Lundbeck A/S Metodo para la preparacion de citalopram.
AR026063A1 (es) 1999-11-01 2002-12-26 Lundbeck & Co As H Metodo para la preparacion de 5-carboxiftalida.
US6310222B1 (en) * 1999-11-01 2001-10-30 Sumika Fine Chemicals Co., Ltd. Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate
CN1398263A (zh) * 1999-12-28 2003-02-19 H·隆德贝克有限公司 制备西酞普兰的方法
PL198803B1 (pl) * 1999-12-30 2008-07-31 Lundbeck & Co As H Sposób wytwarzania 5-cyjano-3H-izobenzofuran-1-onu
IL150561A0 (en) * 2000-01-14 2003-02-12 Lundbeck & Co As H Method for the preparation of 5-cyanophthalide
US6433196B1 (en) 2000-02-17 2002-08-13 Sumika Fine Chemicals Co., Ltd. Production method of citalopram, intermediate therefor and production method of the intermediate
IES20010143A2 (en) * 2000-02-24 2001-07-25 Lundbeck & Co As H Method for the preparation of citalopram
FR2805812A1 (fr) * 2000-02-24 2001-09-07 Lundbeck & Co As H Procede de preparation du citalopram
IES20010157A2 (en) 2000-03-03 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
JP2003527387A (ja) 2000-03-13 2003-09-16 ハー・ルンドベック・アクチエゼルスカベット シタロプラムの製造方法
NL1017500C1 (nl) 2000-03-13 2001-04-26 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
CN1427835A (zh) * 2000-03-13 2003-07-02 H·隆德贝克有限公司 5－取代的1－(4－氟苯基)－1,3－二氢异苯并呋喃的分步烷基化
SK14512002A3 (sk) 2000-03-14 2003-03-04 H. Lundbeck A/S Spôsob výroby citalopramu, medziprodukt a citalopram výrobený týmto spôsobom
EP1274699A1 (en) * 2000-03-16 2003-01-15 H. Lundbeck A/S Method for the preparation of 5-cyano-1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
US6977306B2 (en) * 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
KR100821912B1 (ko) * 2000-05-12 2008-04-16 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조 방법
AR032455A1 (es) * 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
IL148525A0 (en) * 2000-07-06 2002-09-12 Lundbeck & Co As H Method for the preparation of citalopram
IL153988A0 (en) * 2000-07-21 2003-07-31 Lundbeck & Co As H Novel compounds and their use as glycine transport inhibitors
IS6021A (is) * 2000-08-10 2001-10-20 H. Lundbeck A/S Lyfjasamsetningar sem innihalda sítalópram
CA2354877C (en) * 2000-08-18 2006-05-02 H. Lundbeck A/S Method for the preparation of citalopram
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
IT1319686B1 (it) * 2000-12-12 2003-10-23 C D Farmasint S R L Procedimento di preparazione di citalopram.
DE60105926T2 (de) 2000-12-22 2005-11-24 H. Lundbeck A/S, Valby Verfahren zur vorbereitung von reinem citalopram
AU2001100399B4 (en) * 2000-12-28 2002-03-21 H Lundbeck As Process for the preparation of pure citalopram
DE10112828C1 (de) * 2000-12-28 2002-11-21 Lundbeck & Co As H Verfahren zur Herstellung von Citalopram
DE10164725B4 (de) * 2000-12-28 2004-08-26 H. Lundbeck A/S Verfahren zur Herstellung von gereinigtem Citalopram
AU2001100195B4 (en) * 2001-01-05 2001-12-20 H Lundbeck As Pharmaceutical composition containing citalopram.
WO2002060886A1 (en) 2001-01-30 2002-08-08 Orion Corporation, Fermion Process for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
WO2002066453A1 (en) * 2001-02-22 2002-08-29 Natco Pharma Limited Process for the preparation of citalopram
GB0105627D0 (en) 2001-03-07 2001-04-25 Cipla Ltd Preparation of phthalanes
US20050085534A1 (en) * 2001-03-09 2005-04-21 Sujay Biwas Process for the preparation of citalopram
PL367480A1 (en) * 2001-05-01 2005-02-21 H.Lundbeck A/S The use of enantiomeric pure escitalopram
BG65271B1 (bg) * 2001-06-18 2007-11-30 H. Lundbeck A/S Метод за получаване на циталопрам
AR034759A1 (es) * 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
IN192057B (ko) * 2001-07-19 2004-02-14 Ranbaxy Lab Ltd
PT1414435E (pt) * 2001-07-31 2005-05-31 Lundbeck & Co As H Composicao cristalina contendo escitalopram
EP1288211A1 (en) * 2001-08-28 2003-03-05 Sekhsaria Chemicals Ltd. Improved process for the manufacture of citalopram hydrobromide from 5-bromophthalide
US6967259B2 (en) * 2001-09-24 2005-11-22 Pharmachem Technologies Limited Process for the preparation of Citalopram intermediate
US7119083B2 (en) * 2001-10-12 2006-10-10 Azevan Pharmaceuticals, Inc. β-Lactamyl vasopressin V1a Antagonists
IN192863B (ko) * 2001-11-13 2004-05-22 Ranbaxy Lab Ltd
IS7239A (is) * 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
AU2003222435A1 (en) * 2002-01-07 2003-07-24 Sun Pharmaceutical Industries Limited Process for the preparation of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
GB2385848A (en) * 2002-02-27 2003-09-03 Cipla Ltd Citalopram salts
GB2387596B (en) * 2002-02-27 2004-02-11 Matrix Lab Ltd Process
GB0204607D0 (en) * 2002-02-27 2002-04-10 Matrix Lab Ltd Process
EP1346989A1 (en) * 2002-03-21 2003-09-24 Jubilant Organosys Limited Improved process for the preparation of citalopram and its hydrobromide
TWI332938B (en) * 2002-03-27 2010-11-11 Bando Chemical Ind Novel 1,3,5-tris(arylamino)benzenes
CA2381341A1 (en) * 2002-04-09 2003-10-09 Torcan Chemical Ltd. Process and intermediates for preparing escitalopram
FI20021421A0 (fi) * 2002-07-30 2002-07-30 Orion Corp Fermion Valmistusmenetelmä
PE20040991A1 (es) 2002-08-12 2004-12-27 Lundbeck & Co As H Separacion de intermediarios para la preparacion de escitalopram
AU2002330730A1 (en) * 2002-08-14 2004-03-03 Natco Pharma Limited Process for the preparation of high purity citalopram and its pharmaceutically acceptable salts
GB2385051B (en) * 2002-08-29 2003-12-24 Max India Ltd Improved process for the preparation of 5-substituted-1 (4-fluorophenyl)-1,3-dihydro isobenzofurans
US6812355B2 (en) 2002-10-22 2004-11-02 Sekhsaria Chemicals Limited Process for the manufacture of citalopram hydrobromide from 5-bromophthalide
PL378275A1 (pl) * 2002-12-23 2006-03-20 H. Lundbeck A/S Bromowodorek escitalopramu i sposób jego wytwarzania
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
WO2004065375A1 (en) * 2003-01-17 2004-08-05 Natco Pharma Limited Processes for the preparation of escitalopram and its precursor
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
ITMI20030479A1 (it) * 2003-03-13 2004-09-14 Adorkem Technology S P A Procedimento per la preparazione di un ciano-isobenzofurano.
EP1486492A3 (en) * 2003-06-10 2005-02-23 Sun Pharmaceuticals Industries Ltd. A process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran.
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
GB0317475D0 (en) * 2003-07-25 2003-08-27 Meditab Specialities Pvt Ltd Product
ITFI20030202A1 (it) * 2003-07-28 2005-01-29 Synteco Spa Processo per la preparazione di derivati del
CN103788089A (zh) * 2003-09-17 2014-05-14 詹森药业有限公司 作为血清素受体调节剂的稠合杂环化合物
PT1506963E (pt) * 2003-10-28 2005-08-31 Adorkem Technology Spa Processo para a preparacao de citalopram
AU2003278409A1 (en) * 2003-10-28 2005-05-19 Krishnaji Upadhye Bhargav Improved process for the manufacture of citalopram hydrobromide
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US8304431B2 (en) * 2003-12-02 2012-11-06 Pharmaneuroboost N.V. Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050176680A1 (en) 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
CN100569765C (zh) * 2003-12-19 2009-12-16 杭州民生药业集团有限公司 西酞普兰中间体晶体碱
TWI339651B (en) * 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
US20080119662A1 (en) * 2004-02-16 2008-05-22 Jubilant Organosys Limted One Spot Synthesis of Citalopram from 5-Cyanophthalide
US20050196453A1 (en) * 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
ITMI20040717A1 (it) * 2004-04-09 2004-07-09 Adorkem Technology Spa Procedimento chemo-enzimatico per la preparazione dell'escitalopram
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
CN1946906A (zh) * 2004-04-29 2007-04-11 吉斯通护岸系统股份有限公司 用于墙、护墙和类似物的饰面
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006021971A2 (en) 2004-08-23 2006-03-02 Sun Pharmaceutical Industries Limited 'process for preparation of citalopram and enantiomers'
US7989645B2 (en) * 2004-08-23 2011-08-02 Sun Pharma Global Fze Process for preparation of citalopram and enantiomers
WO2006102308A2 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin v1b antagonists
WO2006103550A1 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Processes for the preparation of citalopram and its intermediate 5-aminophthalide
AU2006239942A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
US7368477B2 (en) 2005-04-22 2008-05-06 Wyeth Benzofuranyl alkanamine derivatives and uses thereof
CA2604916A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
CA2603900A1 (en) * 2005-04-22 2006-11-02 Wyeth Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
TWI358407B (en) 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
EP2317316A3 (en) 2005-07-08 2011-06-15 Braincells, Inc. Methods for identifying agent and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
DK1910346T3 (da) * 2005-07-19 2019-05-27 Azevan Pharmaceuticals Inc Beta-lactamyl fenylalanin, cystein og serin vasopressin antagonist
NZ564789A (en) * 2005-07-22 2010-07-30 Myriad Genetics Inc High drug load formulations and dosage forms
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
CN101309924A (zh) * 2005-11-14 2008-11-19 H.隆德贝克有限公司 依地普仑的制备方法
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2644662A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2026813A2 (en) * 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
KR20090064418A (ko) * 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP4927497B2 (ja) * 2006-10-25 2012-05-09 株式会社シスコ 無湿乾燥用ホッパー装置
CN100457747C (zh) * 2006-11-21 2009-02-04 浙江大学 抗抑郁药西酞普兰关键中间体5-氰基苯酞的制备工艺
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
WO2008086483A2 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
EP1988086B2 (en) 2007-04-23 2014-11-26 Synthon B.V. Process for resolving citalopram via its (S)-enriched citalopram tartrate compound.
NZ580738A (en) * 2007-05-18 2012-02-24 Cipla Ltd Process for the preparation of escitalopram
US20080312318A1 (en) * 2007-06-14 2008-12-18 Protia, Llc Deuterium-enriched escitalopram
EP2017271A1 (en) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Process for the preparation of escitalopram
US8022232B2 (en) * 2007-09-11 2011-09-20 H. Lundbeck A/S Method for manufacture of escitalopram
KR101103118B1 (ko) * 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
EP2288345B1 (en) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psycho-pharmaceuticals
EP2116231A1 (en) 2008-05-07 2009-11-11 Hexal Ag Granulate comprising escitalopram oxalate
US20100087664A1 (en) * 2008-10-07 2010-04-08 Ravindra Vedantham Preparation of citalopram and salts thereof
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2735411T3 (es) 2009-10-23 2019-12-18 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de orexina
JP2013535425A (ja) 2010-07-01 2013-09-12 アゼヴァン ファーマシューティカルズ，インコーポレイテッド 心的外傷後ストレス障害を治療する方法
WO2013100870A1 (en) 2011-12-02 2013-07-04 Mahmut Bilgic New antipsychotic compositions
WO2013081567A1 (en) 2011-12-02 2013-06-06 Mahmut Bilgic Effervescent antipsychotic formulations
WO2013110313A1 (en) * 2012-01-23 2013-08-01 H. Lundbeck A/S Selective allosteric modulators of the serotonin transporter
US9802925B2 (en) 2014-03-28 2017-10-31 Azevan Pharmaceuticals, Inc. Compositions and methods for treating neurodegenerative diseases
SI3426251T1 (sl) 2016-03-10 2022-07-29 Janssen Pharmaceutica Nv Postopki za zdravljenje depresije z antagonisti receptorja oreksina-2
AU2018333051B2 (en) 2017-09-15 2024-03-21 Azevan Pharmaceuticals, Inc. Compositions and methods for treating brain injury
US20240024288A1 (en) 2019-07-19 2024-01-25 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (ko) * 1965-03-18

Also Published As

Publication number Publication date
IE44055L (en) 1977-07-14
ATA947276A (de) 1980-04-15
JPS6135986B2 (ko) 1986-08-15
NZ183001A (en) 1978-06-02
CH632259A5 (de) 1982-09-30
DK143275B (da) 1981-08-03
DK143275C (da) 1982-01-18
FR2338271A1 (fr) 1977-08-12
DK13177A (da) 1977-07-15
NL7700244A (nl) 1977-07-18
AU509445B2 (en) 1980-05-15
ES454980A1 (es) 1978-04-01
ZA7757B (en) 1977-11-30
NO770109L (no) 1977-07-15
AU2107377A (en) 1978-07-13
DE2657013C2 (de) 1985-11-14
FI63754B (fi) 1983-04-29
NL192451C (nl) 1997-08-04
SE7614201L (sv) 1977-07-15
BE850401A (fr) 1977-07-14
DE2657013A1 (de) 1977-07-28
NO147243B (no) 1982-11-22
CH632258A5 (de) 1982-09-30
US4136193A (en) 1979-01-23
CA1094087A (en) 1981-01-20
AT359488B (de) 1980-11-10
IE44055B1 (en) 1981-07-29
SE429551B (sv) 1983-09-12
NO1996001I1 (no) 1996-01-05
NL970031I2 (nl) 1997-10-01
FR2338271B1 (ko) 1982-11-05
NL192451B (nl) 1997-04-01
NL970031I1 (nl) 1997-10-01
NO147243C (no) 1983-03-02
FI63754C (fi) 1983-08-10
GB1526331A (en) 1978-09-27
JPS52105162A (en) 1977-09-03
FI770073A (ko) 1977-07-15

Similar Documents

Publication Publication Date Title
CH626886A5 (ko)
DE68921672T2 (de) Enantiomere und ihre Trennung.
DE2500110A1 (de) 3-aryloxy-3-phenylpropylamine und verfahren zu ihrer herstellung
DE1643262C3 (de) i-Phenoxy^-hydroxy-S-alklyaminopropane, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE1543715A1 (de) Verfahren zur Herstellung von basischen Derivaten von Phthalanen und Isochromanen
DE2727144C3 (de) Verwendung bestimmter Chinolinderivate
DE3204960A1 (de) Corynanthein-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE2451474A1 (de) Neue phenylpropenylaminderivate
DE2507429C2 (de) Aminosäureester, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2638850C2 (de) 2-Amino-N↑1↑-(1-phenyl-2-methyl-2-propyl)-propionsäureamide, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
DE1915230A1 (de) Hydroxyphenylalkylaminderivate und Verfahren zu deren Herstellung
DE2621535A1 (de) Phenyl-piperidinderivate und deren salze, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
AT360001B (de) Verfahren zur herstellung von neuen phthalan- -derivaten und ihren pharmazeutisch ver- traeglichen saeureadditionssalzen
DE1922280C3 (de) l-Methyl-5-(3'-dimethylaminopropyliden)-5Hdibenzo [a,d] -cyelohepten-N- oxid und dessen Säureadditionssalze, sowie Verfahren zu deren Herstellung und diese Verbindungen enthaltende Präparate
AT360002B (de) Verfahren zur herstellung von neuen phthalan- -derivaten und ihren pharmazeutisch ver- traeglichen saeureadditionssalzen
DE2522218B2 (de) Zusammensetzung für die Human- oder Veterinärmedizin, Methylaminderivate und Verfahren zu deren Herstellung
DE2348577A1 (de) L-amino-4-phenyltetralin-derivate und diese enthaltende pharmazeutische zubereitung
CH623562A5 (ko)
DE2166662C3 (de) Dibenzothiazepinderivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
DE2738131A1 (de) Aminoketone, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE2751905C2 (ko)
DE3640829A1 (de) Neue 1-aryloxy-3-amino-2-propanole, ihre herstellung und verwendung
DE2204989C3 (de) 2-Phenyl-3-(beta-dlmethylaminopropionyl)benzoturan und dessen pharmakologisch verträgliche Säureadditionssalze sowie diese Verbindungen enthaltende Arzneimittel
DE3706399A1 (de) Mittel mit antidepressiver wirkung
DE2227842C3 (de) Diphenylcyclopentane und diese enthaltende Arzneimittel

Legal Events

Date Code Title Description
PFA Name/firm changed

Owner name: H. LUNDBECK A/S

PUE Assignment

Owner name: H. LUNDBECK & CO., A/S

SPCF Supplementary protection certificate filed

Free format text: IKS 49970, 901214

SPCG Supplementary protection certificate granted

Free format text: IKS 49970/901214, 951024, EXPIRES:20020112

PL Patent ceased